SCHEMBL25913675

SCHEMBL25913675

CC(=O)NCCOCCOCCOCCCC(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HIF1A Q16665 1/20 0.42
MTNR1A P48039 4/20 0.38
MTNR1B P49286 4/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
PAOX Q6QHF9 3/20 0.36
TSHR P16473 2/20 0.35
ADRA1A P35348 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ZDHHC7 Q9NXF8 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22793879 1.00 MEN1 (0.50) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL23560063 1.00 MEN1 (0.50) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL21106575 0.98 MEN1 (0.47) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL25881434 0.91 KDM4E (0.48) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL25489153 0.89 MEN1 (0.53) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL24496106 0.89 MEN1 (0.53) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL13251380 0.87 MEN1 (0.50) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL21106551 0.86 KDM4E (0.53) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL21106927 0.86 KDM4E (0.52) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL24379950 0.84 KMT2A (0.58) MEN1KMT2ATSHRSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 MEN1 3175/4885KMT2A 1513/4885MAPK1 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.